Abiopharma

TARSUS PHARMACEUTICALS, INC. (TARS) Reports the reporting period Financial Results TARSUS PHARMACEUTICALS, INC. (TARS) announced its financial results for the period ending the reporting period. Key Financial Highlights:

• Revenue: 9396
• Net Income: Not disclosed
• EPS: Not disclosed
• Cash and equivalents: 102192
  • 25%, formerly known as TP
  • 03, is a novel prescription eye drop designed to treat Demodex blepharitis by targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials involving over 800 patients with twice
  • daily dosing for six weeks. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment
    • targeting and eradicating the root cause of the disease – Demodex mite infestation. XDEMVY was evaluated in two pivotal trials involving over 800 patients with twice-daily dosing for six weeks. Both trials met the primary endpoint and all secondary endpoints, with statistical significance and no serious treatment-related adverse events. Most patients found the XDEMVY eye drop to be neutral to very comfortable. The most common ocular adverse reactions observed in the studies were instillation site stinging and burning which was reported in 10% of patients. Other ocular adverse reactions reported by less than 2% of patients were chalazion/hordeolum (stye) and punctate keratitis.XDEMVY Indication and Important Safety InformationINDICATIONS AND USAGEXDEMVY is indicated for the treatment of Demodex blepharitis.Most common side effects: The most common side effect in clinical trials was stinging and burning in 10% of patients. Other side effects in less than 2% of patients were chalazion/hordeolum and punctate keratitis.For additional information, please see full prescribing information available at https://xdemvy.com/.About TP-03TP-03 (lotilaner ophthalmic solution) 0.25% is a novel therapeutic designed to treat Demodex blepharitis by targeting and eradicating the root cause of disease – Demodex mite infestation. It was approved by the FDA in 2023
    • expected in the first half of 2027